Filing Flows › Schrodinger (SDGR) › Q3 2026 › vs Q3 2025
Schrodinger (SDGR) Q3 2026 vs Q3 2025 (year over year)
Schrodinger's revenue rose $10.2M (+19%) from $54.3M in Q3 2025 to $64.5M in Q3 2026. The biggest changes: Drug discovery +$11.2M (+86%); Contribution −$3.2M (-60%); Software products and services +$2.2M (+6%).
Schrodinger, Q3 2026: revenue $64.5M (+19% year over year), operating margin -40.5%, net loss $37.7M, operating cash flow −$47.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Hosted software | $17.2M | $11.6M | $5.7M | +49% |
| On-premise software | $13.4M | $15.9M | −$2.6M | -16% |
| Software maintenance | $4.6M | $6.8M | −$2.3M | -33% |
| Professional services | $3.0M | $1.6M | $1.4M | +87% |
| Software products and services | $38.2M | $35.9M | $2.2M | +6% |
| Drug discovery | $24.2M | $13.0M | $11.2M | +86% |
| Contribution | $2.2M | $5.4M | −$3.2M | -60% |
| Revenue | $64.5M | $54.3M | $10.2M | +19% |
| Net loss | $37.7M | $32.8M | $4.9M | +15% |
| Costs & expenses | $102M | $100M | $1.8M | +2% |
| Operating costs | $90.6M | $100M | −$9.7M | -10% |
| Interest & other, net | $11.4M | −$13.3M | $24.7M | — |
| Income tax | $156K | $162K | −$6K | -4% |
| Cost of revenue | $26.2M | $26.3M | −$47K | -0.2% |
| Research & development | $34.1M | $42.8M | −$8.7M | -20% |
| Sales & marketing | $10.0M | $9.5M | $516K | +5% |
| General & admin | $20.3M | $21.7M | −$1.5M | -7% |
| Operating cash sources | $57.0M | $74.2M | −$17.2M | -23% |
| Depreciation & amortization | $1.5M | $1.5M | −$4K | -0.3% |
| Share-based compensation | $7.9M | $10.8M | −$2.9M | -27% |
| Cash used in operations | $47.6M | $61.9M | −$14.3M | -23% |
| Net loss absorbed | $37.7M | $32.8M | $4.9M | +15% |
| Working capital & other | $19.3M | $41.4M | −$22.1M | -53% |
Questions
How much did Schrodinger's revenue grow year over year in Q3 2026?
Schrodinger's revenue rose $10.2M (+19%) from $54.3M in Q3 2025 to $64.5M in Q3 2026.
What drove Schrodinger's revenue change in Q3 2026?
Drug discovery +$11.2M (+86%); Contribution −$3.2M (-60%); Software products and services +$2.2M (+6%).